Literature DB >> 16953450

Clinical and radiological features related to the growth potential of meningioma.

Hidetoshi Kasuya1, Osami Kubo, Masahiko Tanaka, Kosaku Amano, Koichi Kato, Tomokatsu Hori.   

Abstract

Clinical and radiological features that help predict the growth potential of meningioma would be beneficial. The purpose of this study is to clarify the characteristics related to proliferating potential using the MIB-1 staining index. We analyzed the relationship of MIB-1 staining indices to characteristics of 342 consecutive patients with meningioma surgically removed between 1995 and 2004 by logistic regression analysis. One hundred and forty-nine of the patients with meningioma were >or=60 in age; 89 male; 48 recurrent; 203 symptomatic; 157 at the skull base; 124 over 20 cm(3); 24 multiple; 136 with edema; 117 with calcification. The MIB-1 staining index in 56 of 296 grade I meningiomas in WHO classification was >or= 3.0; in 27 of 28 grade II; and in 17 of 18 grade III, respectively. Logistic regression analysis demonstrated that male (odds ratio [OR], 2.374, p=0.003), recurrence (OR, 7.574, p=0.0001), skull base (OR, 0.540, p=0.035), calcification (OR, 0.498, p=0.019) were independent risk factors for a high MIB-1 staining index (>or=3.0); age, symptomatic, volume, multiple, edema were not. Male, recurrence, non-skull base, absence of calcification are independent risk factors for a high proliferative potential. These should be taken into consideration when managing meningiomas.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16953450      PMCID: PMC1564192          DOI: 10.1007/s10143-006-0039-3

Source DB:  PubMed          Journal:  Neurosurg Rev        ISSN: 0344-5607            Impact factor:   3.042


Introduction

An estimated 2–3% of the population has an incidental asymptomatic meningioma in autopsy studies [14, 20]. With the wider use of CT and MRI, many meningiomas are discovered as incidental findings during investigation for unrelated symptoms [9, 13, 16, 17, 20, 21]. The growth potential of meningiomas varies. Some meningiomas remain unchanged in size for a long period, whereas others grow rapidly [15]. Sex, age, initial tumor size, and calcification were reported to be related to the tumor growth judging from follow-up scans [9, 13, 16, 17, 21]. The nuclear antigen Ki-67 expressed by proliferating cells has become available for routinely processed paraffin section. The MIB-1 antibody detects an epitope on the Ki-67 antigen, a nuclear protein present only during active phase of the cell cycle (G1, S, G2, and M) [2]. Several studies investigated how Ki-67 labelling indices could help to predict recurrence [1, 3, 4, 6–8, 11, 12, 18, 19]. An increased MIB-1 staining index was highly correlated with a shorter tumor volume doubling time [12]. In the cases that showed an MIB-1 of ≥ 3%, the tumor volume doubling time was <2 years. Nakaguchi et al. [12] found the formula which can calculate tumor doubling time (Td) from the MIB-1 staining index at surgery: log Td=31.4–0.14×MIB-1 SI (R2=0.556). The time interval to the next recurrence for recurrent meningiomas is associated with the MIB-1 staining index. Meningiomas with MIB-1 staining index of 3% or higher had a significantly higher tendency of recurrence [11]. Although these cell kinetics methods are valuable for growth potential, they can be applied only after the verification of pathology [15]. The purpose of this study was to clarify the clinical and radiological features related to meningioma proliferation using the MIB-1 staining index. Sex, age, calcification, edema, symptom, size, and shape of tumor were already reported to be related to the tumor growth and MIB-1 staining index [1, 3, 4–8, 11–13, 16–19, 21]. The results, however, were inconsistent because of a lack of sufficient case number and inadequate statistical analysis. Independent risk factors for high growth rate should be determined. We analyzed the relationship of MIB-1 staining indices to the characteristics of 342 consecutive patients with meningioma surgically removed between 1995 and 2004 by logistic regression analysis.

Materials and methods

Three hundred and forty-two patients with meningiomas were surgically treated in our department of neurosurgery between 1995 and 2004. Radiological features were analyzed by CT scans and/or MRI. Location of the tumor was classified as follows: convexity, falx, parasagittal, sylvian fissure, tentorial, ventricular, foramen magnum, olfactory groove, petroclival, petrous, sphenoid ridge, and tuberculum sellae. The latter six locations were considered as skull base. The tumor volume was calculated using the formula: length × depth × width × 0.5 [9]. When patients had multiple meningiomas, only the largest tumor was included. On the basis of conventional CT and bone window CT, patients were divided into two groups according to the low density area around the tumor and calcification in the tumor. A low density area due to surgical scar was not included in edema in patients with recurrent meningioma. The tumors were histologically classified according to the World Health Organization classification of tumors [10]. An avidin-biotin immunoperoxidase or simple stain MAX-peroxidase (Nichirei, Tokyo) technique was used to perform MIB-1 monoclonal antibody (DAKO, Denmark) assay in selected sections of each case. All tissue sections were examined at high-power magnification (×400). The number of cells stained positively with MIB-1 and the total number of tumor cells were counted in several representative fields containing more than 1,000 cells. Their ratio was indicated as the MIB-1 staining index (%).

Statistical analysis

All data were stored on a personal computer and analyzed using commercially available statistical software (SPSS version 12.0, SPSS Inc.). Chi-squired analysis was used to compare the MIB-1 staining index to characteristics of patients with meningioma. All variables were included in a logistic regression model to determine which variables were independently associated with a high MIB-1 staining index (≥3.0). Significance was judged at a value of p<0.05 for all analyses.

Results

Table 1 shows the characteristics and MIB-1 staining index of the 342 patients. One hundred and forty-nine of patients with meningioma were ≥60 in age; 89 male; 48 recurrent; 203 symptomatic; 157 at the skull base; 124≥20 cm3 in volume; 24 multiple; 136 with edema; 117 with calcification. We compare these characteristics to the MIB-1 staining index. We divided them into two groups: <3.0 and ≥3.0 [11]. The MIB-1 staining index in 100 of 342 meningiomas was > 3.0. Sex (p=0.0001), recurrence (p=0.0001), symptomatic (p=0.013), volume (p=0.014), edema (p=0.001), and calcification (p=0.0001) were correlated with the MIB-1 staining index by chi-square test; age, skull base, and multiple were not.
Table 1

Characteristics and MIB-1 staining index in 342 meningiomas

 MIB-1 staining index (%) 
Factor<3.0≥3.0P Value
Age (years)0.937
-496524
50-7232
60-7934
70-2610
Sex (male/female)46/19643/570.0001
Recurrence (yes/no)14/22834/660.0001
Symptomatic (yes/no)133/10970/300.013
Skull base (yes/no)119/12338/620.059
Volume (cm3)0.014
-9.911337
10-5315
20-7648
Multiple (yes/no)15/2279/910.244
Edema (yes/no)82/16054/460.001
Calcification (yes/no)97/14520/800.0001
Total242100
Characteristics and MIB-1 staining index in 342 meningiomas Meningothelial, transitional, and fibrous meningiomas were the three major subtypes, and they accounted for about three fourth of the total. Two hundred and ninety-six meningiomas belonged to grade I; 28 grade II; and 18 grade III. MIB-1 staining index in 56 of 296 grade I meningiomas was ≥ 3.0; that in 27 of 28 grade II; and that in 17 of 18 grade III, respectively (Table 2).
Table 2

Histological subtypes and MIB-1 staining index of 342 meningiomas

SubtypeMIB-1 staining index (%)Total
<3.0≥3.0
Grade I
Meningothelial 10628134
Fibrous671380
Transitional431356
Psammomatous606
Angiomatous13215
Microcystic101
Secretory101
Lymphoplasmacyte-rich101
Metaplastic202
24056296
Grade II
Atypical12627
Chordoid011
12728
Grade III
Rhabdoid011
Papillary112
Anaplastic01515
11718
Total242100342
Histological subtypes and MIB-1 staining index of 342 meningiomas Logistic regression analysis demonstrated that male (odds ratio [OR], 2.374, p=0.003), recurrence (OR, 7.574, p=0.0001), skull base (OR, 0.540, p=0.035), calcification (OR, 0.498, p=0.019) were independent risk factors for a high MIB-1 staining index (≥ 3.0); age, symptomatic, volume, multiple, and edema were not (Table 3).
Table 3

Logistic regression analysis for factors independently related to MIB-1 staining index

FactorOdds ratio95%CIP Value
Age1.1090.841–1.4610.464
Sex2.3741.336–4.2190.003
Recurrence7.5743.558–16.1240.0001
Symptomatic1.4680.774–2.7840.240
Skull base0.5400.305–0.9560.035
Volume1.3320.944–1.8790.103
Multiple1.0270.398–2.6510.957
Edema1.5080.838–2.7110.170
Calcification0.4980.278–0.8920.019
Logistic regression analysis for factors independently related to MIB-1 staining index

Discussion

We analyzed the relationship of the MIB-1 staining indices to the characteristics of 342 consecutive patients with meningioma surgically removed between 1995 and 2004 by logistic regression analysis. Logistic regression analysis demonstrated that male (odds ratio [OR], 2.374, p=0.003), recurrence (OR, 7.574, p=0.0001), skull base (OR, 0.540, p=0.035), calcification (OR, 0.498, p=0.019) were independent risk factors for a high MIB-1 staining index (≥ 3.0); age, symptomatic, volume, multiple, and edema were not. The relationship between the growth rate or MIB-1 staining index and age has been controversial: a higher MIB-1 staining index and higher growth rate were observed for younger patients [11, 13, 21]; but not in other reports [1, 12, 15, 19]. Our series of 342 patients with meningioma showed no relation. It is well known that atypical and anaplastic meningiomas are predominant in males [10]. Matsuno et al. [11] reported that the mean MIB-1 staining index in 50 male patients was 5.5%, whereas that in 77 female patients was 2.7%. Our findings show that male (odds ratio [OR], 2.374, p=0.003) was an independent risk factor for a high MIB-1 staining index. We also found a higher MIB-1 staining index in males even in grade I meningioma (MIB-1 staining index in 32 of 226 females, and in 24 of 70 males was ≥ 3.0, p=0.0001, chi-squire test). Recurrence (OR, 7.574, p=0.0001) was the most significant independent risk factor for a high MIB-1 staining index (≥ 3.0). Therefore, we propose prompt management for recurrent meningiomas. In most of the recurrent meningiomas, the MIB-1 staining index was higher at the time of recurrence than at the time of initial surgery [1, 11, 19]. Changes in histological morphology and malignant transformation are also known in meningiomas. Although there is a significant difference in the MIB-1 staining index between symptomatic and non-symptomatic meningiomas by chi-square test, symptomatic is not an independent risk factor for a high MIB-1 staining index. Meningiomas commonly present with seizure disorders, and are associated with location, perilesional edema, and convexity location. Symptoms and signs of elevated intracranial pressure could be due to the large size of meningioma itself, or to the pronounced cerebral swelling resulting from reactive vasogenic edema. Focal neurological deficits caused by meningiomas are generally related to direct local brain, cranial-nerve compression, and can be predicted from the site of origin of the tumor [20]. Thus, symptomatic meningioma may not be related to a high MIB-1 staining index. The growth rate of incidental meningioma may be similar to that of symptomatic meningioma. Our results demonstrated that skull base (OR, 0.540, p=0.035) is an independent risk factor for a high MIB-1 staining index. No relationship has been reported between the MIB-1 staining index and the location of meningiomas [15, 19]. In general, the surgical risk for meningiomas is higher in skull base. A low proliferative potential in skull base meningiomas should be taken into consideration especially when treating elderly patients with asymptomatic meningiomas [9, 16]. Although there was a significant difference of the MIB-1 staining index in tumor size by chi-square test [15], tumor size is not an independent risk factor for a high MIB-1 staining index. The tumor volume is associated with the annual growth rate but not with doubling time [13, 16, 21]. Assuming that a tumor shows a constant relative volume increase, larger tumors will show higher growth rates if the annual volume increase is expressed in absolute values. Large tumors should be carefully observed even though the initial volume is not a risk factor for a high MIB-1 index, and it is not correlated with doubling time. The etiology of peritumoral brain edema associated with meningiomas is multifactorial. Factors that may influence the etiology of peritumoral edema include tumor size, histological subtypes, vascularity, venous stasis, and brain invasion [1, 4]. Ide et al. [4] found a significant correlation of both the MIB-1 staining index and tumor size with the extent of edema. A high MIB-1 staining index itself did not seem to be directly responsible for perifocal edema, since our logistic regression analysis demonstrated that edema is not an independent risk factor for a high MIB-1 index [15]. Tumors with calcification grew significantly less than those without calcification [9, 13, 16]. Absence of calcification on CT correlated strongly with doubling time [5]. Diffusely calcified meningiomas had a low mean MIB-1 staining index of 0.57%. Focally calcified tumors showed a relatively low proliferative potential (0.92%) compared with that of noncalcified tumors (1.75%) [15]. The results are always consistent when the relationship between calcification and proliferative potential or growth rate is compared. We also confirmed this characteristic in meningioma (OR, 0.498, p=0.019). In conclusion, male, recurrence, non-skull base, absence of calcification are independent risk factors for a high proliferative potential. These should be taken into consideration when managing meningiomas.
  20 in total

1.  Incidence and clinical features of asymptomatic meningiomas.

Authors:  J Kuratsu; M Kochi; Y Ushio
Journal:  J Neurosurg       Date:  2000-05       Impact factor: 5.115

2.  Growth of incidental meningiomas.

Authors:  Y Yoneoka; Y Fujii; R Tanaka
Journal:  Acta Neurochir (Wien)       Date:  2000       Impact factor: 2.216

3.  Histopathology and MIB-1 labeling index predicted recurrence of meningiomas: a proposal of diagnostic criteria for patients with atypical meningioma.

Authors:  Donald Ming-Tak Ho; Chih-Yi Hsu; Ling-Tan Ting; Hung Chiang
Journal:  Cancer       Date:  2002-03-01       Impact factor: 6.860

4.  Natural history of elderly patients with asymptomatic meningiomas.

Authors:  M Niiro; K Yatsushiro; K Nakamura; Y Kawahara; J Kuratsu
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-01       Impact factor: 10.154

5.  The growth rate of intracranial meningiomas and its relation to histology. An analysis of 43 patients.

Authors:  J Jääskeläinen; M Haltia; E Laasonen; T Wahlström; S Valtonen
Journal:  Surg Neurol       Date:  1985-08

6.  The expression of survivin and Ki-67 in meningiomas: correlation with grade and clinical outcome.

Authors:  Fazilet Kayaselçuk; Suzan Zorludemir; Nebil Bal; Bulent Erdogan; Seyda Erdogan; Tahsin Erman
Journal:  J Neurooncol       Date:  2004 Mar-Apr       Impact factor: 4.130

Review 7.  Meningiomas.

Authors:  Ian R Whittle; Colin Smith; Parthiban Navoo; Donald Collie
Journal:  Lancet       Date:  2004-05-08       Impact factor: 79.321

8.  Proliferation rate of intracranial meningiomas as defined by the monoclonal antibody MIB-1: correlation with peritumoural oedema and other clinicoradiological and histological characteristics.

Authors:  Paulo Henrique Aguiar; Ana Maria Tsanaclis; Oswaldo Inácio Tella; José Pindaro Plese
Journal:  Neurosurg Rev       Date:  2003-04-08       Impact factor: 3.042

9.  The Ki-67 proliferation antigen in meningiomas. Experience in 600 cases.

Authors:  F Roser; M Samii; H Ostertag; M Bellinzona
Journal:  Acta Neurochir (Wien)       Date:  2003-12-22       Impact factor: 2.216

10.  The natural history of incidental meningiomas.

Authors:  Makoto Nakamura; Florian Roser; Julia Michel; Cornelius Jacobs; Madjid Samii
Journal:  Neurosurgery       Date:  2003-07       Impact factor: 4.654

View more
  41 in total

1.  Technetium Tc99m-tetrofosmin brain single-photon emission CT for the diagnosis of malignant meningiomas.

Authors:  G A Alexiou; S Voulgaris; S Tsiouris; A D Fotopoulos; A P Kyritsis; K S Polyzoidis
Journal:  AJNR Am J Neuroradiol       Date:  2009-02-04       Impact factor: 3.825

2.  Meningiomas: skull base versus non-skull base.

Authors:  Torstein R Meling; Michele Da Broi; David Scheie; Eirik Helseth
Journal:  Neurosurg Rev       Date:  2018-04-07       Impact factor: 3.042

3.  Incidental finding of tumor while investigating subarachnoid hemorrhage: ethical considerations and practical strategies.

Authors:  Doniel Drazin; Kevin Spitler; Milos Cekic; Ashish Patel; George Hanna; Ali Shirzadi; Ray Chu
Journal:  Sci Eng Ethics       Date:  2012-10-13       Impact factor: 3.525

4.  Clinical features and surgical management of intracranial meningiomas in the elderly.

Authors:  Junkoh Yamamoto; Mayu Takahashi; Masaru Idei; Yoshiteru Nakano; Yoshiteru Soejima; Daisuke Akiba; Takehiro Kitagawa; Kunihiro Ueta; Ryo Miyaoka; Shigeru Nishizawa
Journal:  Oncol Lett       Date:  2017-05-16       Impact factor: 2.967

Review 5.  Pediatric infratentorial meningiomas: a series of 19 cases and review of the literature.

Authors:  Hai Liu; Wei Luo; Jiaxin Li; Jun Yang; Yulun Xu
Journal:  Childs Nerv Syst       Date:  2017-02-28       Impact factor: 1.475

6.  Mitotic Index is an Independent Predictor of Recurrence-Free Survival in Meningioma.

Authors:  Adriana Olar; Khalida M Wani; Erik P Sulman; Alireza Mansouri; Gelareh Zadeh; Charmaine D Wilson; Franco DeMonte; Gregory N Fuller; Kenneth D Aldape
Journal:  Brain Pathol       Date:  2014-10-29       Impact factor: 6.508

7.  Imaging and diagnostic advances for intracranial meningiomas.

Authors:  Raymond Y Huang; Wenya Linda Bi; Brent Griffith; Timothy J Kaufmann; Christian la Fougère; Nils Ole Schmidt; Jöerg C Tonn; Michael A Vogelbaum; Patrick Y Wen; Kenneth Aldape; Farshad Nassiri; Gelareh Zadeh; Ian F Dunn
Journal:  Neuro Oncol       Date:  2019-01-14       Impact factor: 12.300

8.  (99m)Tc-Tetrofosmin brain SPECT in the assessment of meningiomas-correlation with histological grade and proliferation index.

Authors:  Andreas D Fotopoulos; George A Alexiou; Ann Goussia; Athanasios Papadopoulos; Athanasios P Kyritsis; Konstantinos S Polyzoidis; Spyridon Voulgaris; Spyridon Tsiouris
Journal:  J Neurooncol       Date:  2008-05-06       Impact factor: 4.130

9.  Imaging and extent of surgical resection predict risk of meningioma recurrence better than WHO histopathological grade.

Authors:  William L Hwang; Ariel E Marciscano; Andrzej Niemierko; Daniel W Kim; Anat O Stemmer-Rachamimov; William T Curry; Fred G Barker; Robert L Martuza; Jay S Loeffler; Kevin S Oh; Helen A Shih; Mykol Larvie
Journal:  Neuro Oncol       Date:  2015-11-22       Impact factor: 12.300

Review 10.  Intracranial meningiomas of atypical (WHO grade II) histology.

Authors:  Leland Rogers; Mark Gilbert; Michael A Vogelbaum
Journal:  J Neurooncol       Date:  2010-08-26       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.